The Healthcare Outlook: Macro Challenges and Biotech Innovations

医疗展望:宏观挑战与生物技术创新

Goldman Sachs Exchanges

2025-09-18

28 分钟
PDF

单集简介 ...

While the healthcare sector has lagged behind the broader markets, there are pockets of innovation. Asad Haider, head of the US Healthcare Business Unit in Goldman Sachs Research, and Amit Sinha, head of Life Sciences Investing in Goldman Sachs Asset Management, discuss their outlook for the industry. This episode was recorded on September 8 and 15, 2025. The opinions and views expressed herein are as of the date of publication, subject to change without notice, and may not necessarily reflect the institutional views of Goldman Sachs or its affiliates. The material provided is intended for informational purposes only, and does not constitute investment advice, a recommendation from any Goldman Sachs entity to take any particular action, or an offer or solicitation to purchase or sell any securities or financial products. This material may contain forward-looking statements. Past performance is not indicative of future results. Neither Goldman Sachs nor any of its affiliates make any representations or warranties, express or implied, as to the accuracy or completeness of the statements or information contained herein and disclaim any liability whatsoever for reliance on such information for any purpose. Each name of a third-party organization mentioned is the property of the company to which it relates, is used here strictly for informational and identification purposes only and is not used to imply any ownership or license rights between any such company and Goldman Sachs. A transcript is provided for convenience and may differ from the original video or audio content. Goldman Sachs is not responsible for any errors in the transcript. This material should not be copied, distributed, published, or reproduced in whole or in part or disclosed by any recipient to any other person without the express written consent of Goldman Sachs. Disclosures applicable to research with respect to issuers, if any, mentioned herein are available through your Goldman Sachs representative or at http://www.gs.com/research/hedge.html. Goldman Sachs does not endorse any candidate or any political party. © 2025 Goldman Sachs. All rights reserved. Learn more about your ad choices. Visit megaphone.fm/adchoices
更多

单集文稿 ...

  • Equity markets are reaching new heights, but one sector has been lagging behind, healthcare.

  • So what's driving this underperformance?

  • And how will upcoming innovations impact future investment opportunities and the sector's outlook?

  • I'm Allison Nathan, and this is Goldman Sachs Exchanges.

  • In today's episode, I'll be speaking with Assad Haider,

  • who leads the team covering the U.S. healthcare sector for Goldman Sachs research.

  • We'll explore the macroeconomic factors and the specific headwinds and tailwinds affecting the industry.

  • Next, we'll turn to Amit Sinha, head of Life Sciences Investing in Goldman Sachs Asset Management,

  • to discuss how investors are navigating the emerging innovations and risks in this sector.

  • Assad, welcome to Exchanges.

  • Thank you for having me.

  • So let's start with a big picture.

  • I'm just looking at my screen.

  • The S&P 500 is at record high levels, but healthcare has not had that performance.

  • In fact, it's substantially underperformed.

  • And if I have my facts right,

  • the healthcare sector's weight in the index has dropped to its lowest point in decades.

  • So let's just start there.

  • What is behind this significant underperformance?

  • You're right.